News

Acceptance and commitment therapy reduced IBD stress, depression
- Author:
- Amy Karon
The 8-week mindfulness course improved stress and depression in patients with inflammatory bowel disease.
News
Meta-analysis generally supports LI-RADS classification accuracy
- Author:
- Amy Karon
But 13% of lesions classified as probably benign (LI-RADS2) were actually hepatocellular carcinomas.
News

NASH: Fastest-growing cause of liver cancer in transplant candidates
- Author:
- Amy Karon
Its prevalence rose nearly 700% between 2002 and 2017.
News

Long-term budesonide oral suspension well tolerated in EoE
- Author:
- Amy Karon
In all, 42% of initial responders maintained a histologic response.
News

AGA Clinical Practice Update: Functional gastrointestinal symptoms in patients with inflammatory bowel disease
- Author:
- Amy Karon
It’s essential to determine whether the symptoms are caused by inflammation or another etiology that can be addressed separately.
News

AGA Guideline: Treatment of mild to moderate ulcerative colitis
- Author:
- Amy Karon
Mesalamine and diazo-bonded 5-aminosalicylic acid are still the primary drugs recommended for treatment.
News

Single-dose tafenoquine appears to prevent malaria relapse
- Author:
- Amy Karon
The drug cut relapse rates in select patients without causing symptomatic anemia.
News
Anaerobically prepared donor FMT led to steroid-free remission of ulcerative colitis
- Author:
- Amy Karon
Eight weeks after FMT, 32% of the donor group achieved steroid-free remission, compared with 9% of the autologous FMT group (odds ratio, 5; P...
News

INPULSIS-ON: Nintedanib shows manageable long-term safety for IPF
- Author:
- Amy Karon
IFP has had a poor prognosis and long-term data on treatment options are needed.
News
Platinum-etoposide, taxanes best for small cell transformed EGFR-mutant lung cancer
- Author:
- Amy Karon
Both platinum-etoposide and taxane therapies produced high response rates (71% each), but patients did not respond to checkpoint inhibitor therapy...
News
Adding veliparib to doublet therapy for NSCLC gives slight boost in PFS
- Author:
- Amy Karon
Median progression-free survival was 6.1 months for veliparib plus cisplatin-etoposide versus 5.5 months for placebo plus cisplatin-etoposide.
News
Low-normal thyroid function tied to advanced fibrosis
- Author:
- Amy Karon
In all, 5.9% of adults with low-normal thyroid function had advanced liver fibrosis, compared with 2.8% of individuals with strict-normal thyroid...
News
Adverse events a potential concern for chemotherapy-nivolumab in advanced gastric cancer
- Author:
- Amy Karon
Adverse events led to dose delays or reductions in 95% of patients. Serious adverse events affected 15% of patients and in most cases led them to...
News
Plerixafor produced dramatic responses in severe WHIM syndrome
- Author:
- Amy Karon
The treatment was effective and well tolerated in patients who could not receive granulocyte colony-stimulating factor therapy.
News

CRP predicts anti-TNF response in ankylosing spondylitis
- Author:
- Amy Karon
A baseline C-reactive protein level more than three times above the upper limit of normal correlated significantly with 12-week etanercept...